The score of Varela et al is based on myeloid and megakaryocytic features, and is associated with patient prognosis.
|
Parameter |
Finding |
Points |
|
neutrophil count |
> 3000 per µL |
0 |
|
|
1000 - 3000 per µL |
1 |
|
|
500 - 999 per µL |
2 |
|
|
< 500 per µL |
3 |
|
platelet count |
> 150,000 per µL |
0 |
|
|
100,000 - 150,000 per µL |
1 |
|
|
50,000 - 99,999 per µL |
2 |
|
|
20,000 - 49,999 per µL |
3 |
|
|
< 20,000 per µL |
4 |
|
megakaryocyte count |
< 1 per 1,000 nucleated cells in the bone marrow |
2 |
|
dysgranulopoiesis |
hypogranular cells >= 20% |
2 |
|
|
abnormal nuclei >= 20% |
2 |
|
dysmegakaryopoiesis |
micromegakaryocytes or large mononuclear forms or multiple small nuclei >= 30% |
2 |
score =
= (points for neutrophil count) + (points for platelet count) + (points for megakaryocyte count) + (points for dysgranulopoiesis) + (points for dysmegakaryopoiesis)
Interpretation:
• minimum score: 0
• maximum score: 15
• scores of 0-1 have best survival, 2-5 intermediate, and >= 6 worst
Specialty: Hematology Oncology, Clinical Laboratory
ICD-10: ,
